This is a routine CEO succession filing with no financial data to trade on. The press release contains only qualitative forward-looking statements. Monitor the upcoming Q2 2026 earnings release for actual financial results and guidance — that will be the next material catalyst for STAA.
Price Chart
Executive Summary
STAAR Surgical appointed Warren Foust as permanent President and CEO (effective August 4, 2026), ending the interim co-CEO structure with CFO Deborah Andrews, who was promoted to EVP and continues as CFO. Foust received a substantial equity package including ~395,000 performance-vesting options with stock price hurdles at $50, $75, and $100 (current stock ~$24), plus time-vesting RSUs and options. The press release touted 'the strongest first half in our Company's history' with 'robust year-over-year growth' and 'increasing profitability,' but no specific financial figures were provided. This is a routine CEO succession and compensation filing — the appointment of an internal candidate who has been in the role on an interim basis is neutral, and the equity grants are standard for a new CEO.
Key Facts
- Warren Foust appointed President and CEO and to the Board, effective August 4, 2026
- Deborah Andrews appointed EVP, continues as CFO; ceases as Interim Co-CEO
- Foust receives base salary of $730,000 annually and target bonus of 100% of base salary (from Feb 2026)
- Foust's equity package includes 67,479 time-vesting RSUs, 121,413 time-vesting options, and 395,494 performance-vesting options with stock price hurdles of $50, $75, and $100 per share
- Performance-vesting options have a 10-year term; time-vesting over 3 years (CEO Grant) and 42 months (2027 Grant)
- Andrews receives options for 8,952 time-vesting shares, 29,159 performance-vesting shares, and 4,975 RSUs
- Foust executed Amended and Restated Severance Agreement (18 months base pay) and Change in Control Agreement (18 months base pay + bonus)
- Press release claims 'strongest first half in Company's history' with 'robust year-over-year growth' but no specific financial figures provided
Financial Impact
CEO equity grants valued at exercise price of $24.12 per share on ~516,000 total options/RSUs; no cash impact on company
Risk Factors
- No specific financial figures provided — all growth claims are qualitative and forward-looking
- CEO equity grants create potential future dilution of ~0.5% of outstanding shares
- Performance-vesting options with $50/$75/$100 hurdles are far out of the money relative to current ~$24 stock price, suggesting management sees significant upside but also risk of no payout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-337197 |
| Document: staa-ex10_3.htm | 0001193125-26-337197 |
| Document: staa-ex10_2.htm | 0001193125-26-337197 |
| Document: staa-20260805.htm | 0001193125-26-337197 |
| Document: staa-ex10_1.htm | 0001193125-26-337197 |
| Document: staa-ex99_1.htm | 0001193125-26-337197 |
| Document: 0001193125-26-337197-index-headers.html | 0001193125-26-337197 |
| Document: 0001193125-26-337197-index.html | 0001193125-26-337197 |
| Document: 0001193125-26-337197.txt | 0001193125-26-337197 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | 8-K | $25.33 | awaiting T+60 | — | $23.23 (−8.29%) |
Aug 6, 2026 11w ago | 8-K | $23.12 | awaiting T+60 | — | $23.23 (+0.48%) |
Jun 22, 2026 18w ago | 8-K | $28.36 $22.41 | ▼ −20.98% | ▼ −24.23% | $23.23 (−18.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $28.90 $23.47 | ▲ +18.79% | ▲ +23.18% | $23.23 (+19.62%) |
May 13, 2026 23w ago | 8-K | $32.01 $25.12 | ▼ −21.52% | ▼ −25.11% | $23.23 (−27.43%) |
Apr 8, 2026 28w ago | 8-K | $25.21 $27.34 | ▲ +8.45% | ▼ −2.33% | $23.23 (−7.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers